Acute Lymphoblastic Leukemia research
Acute Lymphoblastic Leukemia research is a research topic within Public Health, Environmental and Occupational Health. Science Explorer counts 40k research works in it since 1950. 19.4% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the epidemiology, genetic basis, treatment, and outcomes of childhood acute lymphoblastic leukemia (ALL). It covers topics such as genetic alterations, minimal residual disease, pharmacogenomics, prognostic factors, and relapse risk. The papers also discuss the challenges and advancements in pediatric oncology for the treatment of childhood leukemia.
- Childhood Cancer
- Acute Lymphoblastic Leukemia
- Genetic Alterations
- Treatment Outcome
- Minimal Residual Disease
- Pharmacogenomics
- Prognostic Factors
- Thiopurine Therapy
- Relapse Risk
- Pediatric Oncology
- Research works
- 40k fractional, since 1950
- In the world top 10%
- 7.8k per year above
- Top-10% rate
- 19.4% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +17% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Acute Lymphoblastic Leukemia research research?
By volume, the United States and China publish the most (2k and 852 works in 2022–2025).
By volume, 2022–2025
- 1 United States 2k works
- 2 China 852 works
- 3 India 407 works
- 4 Brazil 358 works
- 5 Germany 240 works
- 6 Japan 232 works
- 7 Italy 222 works
- 8 United Kingdom 212 works
- 9 France 199 works
- 10 Canada 165 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Acute Lymphoblastic Leukemia research research?
By volume in 2022–2025, The University of Texas MD Anderson Cancer Center publishes the most Acute Lymphoblastic Leukemia research research, followed by St. Jude Children's Research Hospital and Chinese Academy of Medical Sciences & Peking Union Medical College.
By volume, 2022–2025
- 1 The University of Texas MD Anderson Cancer Center United States 124 works
- 2 St. Jude Children's Research Hospital United States 63 works
- 3 Chinese Academy of Medical Sciences & Peking Union Medical College China 31 works
- 4 Dana-Farber Cancer Institute United States 30 works
- 5 Moffitt Cancer Center United States 26 works
- 6 All India Institute of Medical Sciences India 26 works
- 7 Institute of Hematology & Blood Diseases Hospital China 25 works
- 8 Baylor College of Medicine United States 25 works
- 9 City of Hope United States 25 works
- 10 Memorial Sloan Kettering Cancer Center United States 24 works
Who are the leading researchers in Acute Lymphoblastic Leukemia research?
The most-cited researchers publishing on Acute Lymphoblastic Leukemia research include Kenneth J. Livak, Gad Getz and Elisabete Weiderpass.
- 1 Kenneth J. Livak 20k citations
- 2 Gad Getz 6.2k citations
- 3 Elisabete Weiderpass 6k citations
- 4 Hagop M. Kantarjian 4k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Acute Lymphoblastic Leukemia research research done?
The largest centres of Acute Lymphoblastic Leukemia research research in 2022–2025 are Houston (United States), Beijing (China), São Paulo (Brazil) and New York (United States). Among places with at least 20 works in it, it is an unusually large share of all research in Lancaster, Memphis and Houston.
Largest cities, 2022–2025
Where it is the local speciality
- LancasterUS · 24.6 works46×
- MemphisUS · 72.7 works22×
- HoustonUS · 171.1 works10×
- TampaUS · 40.7 works8.6×
Location quotient: how much more of its research is in Acute Lymphoblastic Leukemia research than the world average.
Where is the best place to study Acute Lymphoblastic Leukemia research?
Among universities, judged by research, Medical University of Lublin, Baylor College of Medicine and Karolinska Institutet score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Medical University of Lublin Poland | 57.2 | 24.3% | 11.8× | 13 | -6.3% |
| 2 | Baylor College of Medicine United States | 56.0 | 17.0% | 9.2× | 24 | +45.6% |
| 3 | Karolinska Institutet Sweden | 53.0 | 25.6% | 3.7× | 11 | +50.2% |
| 4 | Medizinische Hochschule Hannover Germany | 49.0 | 23.4% | 7.0× | 10 | +2.0% |
| 5 | Post Graduate Institute of Medical Education and Research India | 48.6 | 11.4% | 8.3× | 18 | +126.1% |
| 6 | University of Alabama at Birmingham United States | 48.0 | 21.2% | 4.2× | 14 | +140.4% |
| 7 | Medical College of Wisconsin United States | 47.1 | 16.2% | 7.7× | 13 | +72.0% |
| 8 | Harvard University United States | 46.6 | 26.7% | 2.0× | 18 | +9.3% |
| 9 | University of Pennsylvania United States | 45.3 | 21.4% | 3.7× | 23 | +30.5% |
| 10 | University of Washington United States | 45.3 | 25.5% | 3.0× | 21 | -8.5% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Acute Lymphoblastic Leukemia research research growing?
Output in 2018–2022 was 17% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Acute Lymphoblastic Leukemia research.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.